Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines
US7427404B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 17, 1994 |
| Grant date | Sep 23, 2008 |
| Priority date | — |
| Expiry date | Jun 17, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K39/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
New pertussis toxin (PT) mutants are described being immunologically active and having reduced or no toxicity, characterized in that at least one of the aminoacid residues Glu129, Asp11, Trp26, Arg9, Phe50, Asp1, Arg13, Tyr130, Gly86, Ile88, Tyr89, Tyr8, Gly 44, Thr53 and Gly80 or subunit's 1 aminoacid sequence is deleted and substituted by a different aminoacid residue selected in the group of natural aminoacids; Bordetella strains capable of providing and secreting said PT mutants and means and methods for obtaining them are also described.The Bordetella strains and the PT mutants produced by them are particularly suitable for the preparation of effective cellular and acellular antipertussis vaccines.(FIG. 1)
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.